Sirenas, a biotechnology company harnessing computational approaches to discover therapeutics derived from the global microbiome, announced that it has entered into a multi-target research collaboration agreement with Bristol-Myers Squibb Company to deploy Sirenas’ drug discovery platform against certain undisclosed challenging therapeutic targets to identify potential drug candidates.
The research collaboration leverages Sirenas’ expertise in applying ATLANTIS, its data mining technology, to identify such potential drug candidates derived from Sirenas’ proprietary chemical library isolated from global microbiome collections.
Under the terms of the collaboration agreement Sirenas and Bristol-Myers Squibb will work together to identify such potential drug candidates. Sirenas will receive an undisclosed up-front payment, funding for research activities and potential success fees from Bristol-Myers Squibb. In addition, Bristol-Myers Squibb has an option to license compounds identified from the collaborative efforts under a separate agreement that will include potential milestones and royalties paid to Sirenas.
“We believe science-focused biopharma companies can benefit from our innovative approaches to access breakthrough chemistry in delivering drug candidates for difficult biological targets,” said Jake Beverage, PharmD., Co-Founder and CEO of Sirenas. “We look forward to a fruitful collaboration with Bristol-Myers Squibb, one of the finest drug discovery teams in the world, to identify potential new therapies to treat the world’s highest unmet medical needs.”